ANALYSIS OF THE PREVALENCE OF VARIOUS FORMS OF ATRIAL FIBRILLATION AND COMPLIANCE OF PREVENTION OF THROMBOEMBOLIC COMPLICATIONS ON THE TERRITORY OF FAMILY POLYCLINICS IN SYRDARYA REGION

Irisov Dj. B., ZakirovN.U., Tolibov A., Turgunboev S.T., Nabibullaeva Sh., Karimova M. Q.

Republican Specialized Scientific and Practical Medical Center of Cardiology. Tashkent, 100052. Irisov Dj.B.

Republican Specialized Scientific and Practical Medical Center of Cardiology. Tashkent, 100052. Zakirov N.U.

Republican Specialized Scientific and Practical Medical Center of Cardiology. Tashkent, 100052. Tolibov A

Tashkent, Chilanzor district, Katta Kani street, Khairabad 13. "Hilolmed" Turgunboev S.T.

Republican Specialized Scientific and Practical Medical Center of Cardiology. Tashkent, Sh Nabibullaeva Sh.

Republican Specialized Scientific and Practical Medical Center of Cardiology. Tashkent, Karimova M.Q.

Introduction: Atrial fibrillation (AF) is the most common cardiac arrhythmia that complicates the course of various cardiovascular diseases, and is also accompanied by the frequent development of thromboembolic complications (TEC), primarily ischemic stroke.

Purpose study is to obtain data on the prevalence of various forms of AF and compliance of the prevention of TEC on the use of anticoagulant agents on the territory of individual family polyclinics (FP) of Syrdarya region (Uzbekistan).

Methods: To achieve this goal, FP№3 of the city of Gulistan and FP№14 of the Gulistan district of the Syrdarya region were randomly selected (urban and rural). With the help of electronic mathematical program were allocated by random selection method for FP№3 -1064 persons, and for FP№14 -812 persons.

Results: in FP№3 in the age group of 40-49years, AF was detected in 1.11%, in the group of 50-59years, AF was detected in 0.56%, in the age category of 60-69years - in 2.27% of those examined. It should be noted that the detection of AF increased with age, reaching a maximum in the category of 90-91years (50%). In the age group over 80years, the prevalence of AF was 12.5%. And when analyzing rural areas (FP№14) in the age group of 50-59 years, AF was detected in 1.31%, and in the group of 60-69years 1.47%. At the outpatient stage, insufficient adequacy of the prevention of TEC was revealed in patients with AF studied both in urban (27%) and rural (25%) clinic.

Conclusion: The prevalence of AF among the adult population of individual clinics in the city of Gulistan (1.03%) is 2 times higher than among the population of a rural clinic (0.49%). At the outpatient stage insufficient adequacy was revealed both in individual urban and rural AF. Thus, more than 70% of patients with AF have a high risk of death and disability.

Keywords: atrial fibrillation, prevalence, anticoagulant therapy, thromboembolic complications, DOAC.

Currently, the estimated prevalence of Atrial fibrillation (AF) in the adult population ranges from 2% to 4%. The prevalence is expected to increase 2.3 times due to the increase in life expectancy of the general population, as well as due to the active search for undiagnosed AF [1,2,3,4].

The problem of ischemic strokes (IS) in patients with AF due to inadequate prevention of thromboembolic complications (TEC) seems to be relevant medically and socially. It was found that the risk of developing IS is considered the highest in the valvular (rheumatic) etiology of AF, 17 times higher than the corresponding indicator of people without AF, and this category of patients is obliged to take warfarin [1,2,5]. In the non-valvular etiology of AF the risk of IS increases up to 5-7 times depending on the presence of risk factors determined by the CHA₂DS₂-VASc score, and the most effective prevention of TEC is carried out by DOAC [2,6,7,8,9]. Thus, determination of the etiologic factor is the key to choosing between warfarin and DOAC. The necessity and choice of the type of pharmacological prevention of TEC depends on etiology and comorbid factors determined by the CHA₂DS₂-VASc score, as well as economic feasibility. The burden of the TEC in AF feasibility study on healthcare caused by thousands of fatal and disabling complications of ischemic stroke amounts to billions of dollars per year in the USA [9,10].

All over the world, the results of registries [3,4,11.12], reflecting the real state of the prevalence of clinical forms of AF and compliance of TEC prevention with recommended standards are widely used in solving these problems. Unfortunately, in Uzbekistan, this problem is poorly studied at the population level. So, according to calculations, in Uzbekistan, as a complication of AF annually up to 20 thousand strokes [13,14,15] 1/3 (7-8 thousand) of them die, and only 10-15% return to full life, the rest (another 8-10 thousand) have various limitations of usual life activities, including severe disability - the need for nursing care. Timely identification of persons suffering from AF and prevention of ischemic stroke in patients with its various clinical forms throughout Uzbekistan could reduce mortality and disability associated with AF by 50% or more.

The purpose study is to obtain data on the prevalence of various forms of AF and compliance with the prevention of TEC on the use of anticoagulant agents with the current recommendations of the ESC (2020) on the territory of individual family polyclinics of Syrdarya region.

Materials and Methods of the Study. Study of data on the prevalence of various forms of AF and compliance of prevention of TEC by the use of anticoagulant agents with current recommendations in the territory of family polyclinics (FP) №3 and

№14 of Syrdarya region. To achieve the set goal, (urban and rural) FP№3 of Gulistan city and FP№14 of Gulistan district of Syrdarya province with a total population of 29577 people (22165 (FP№3) and 7412 (FP№14) population, respectively) were randomly selected.

Random selection was performed using computer programs with the function of random number generator in Microsoft Excel program. Taking into account the table (Table N \ge 1 [16,17]), not exceeding 5% error of the number of observation units at the accuracy of the total set of 29577 persons (22165 (FPN \ge 3) and 7412 (FPN \ge 14)) of the population with the help of electronic mathematical program were allocated by random selection method for FPN \ge 3 of Gulistan city 1064 persons, and for FPN \ge 14 of Gulistan district 812 persons.

The scheme of the study formation is shown in Table №2. In order to assess compliance of TEC prevention with the current ESC recommendations at the outpatient stage, we studied outpatient records of selected adult patients (over 18 years of age) of FP№3 and FP№14, as well as through active calls and consultations

Table №1.

complex.									
	0,01-1%	0,02-2%	0,03-3%	0,04-4%	0,05-5%				
1000	909	714	526	286	286				
2000	1667	1111	714	476	333				
3000	2308	1364	811	517	353				
4000	2857	1538	869	540	364				
5000	3333	1667	909	555	370				
6000	3750	1765	937	566	375				
7000	4118	1842	959	574	378				
8000	4444	1905	976	580	381				
9000	4737	1956	989	584	383				
10000	5000	2000	1000	588	385				
11000	5238	2037	1009	591	386				
12000	5454	2069	1017	594	387				
13000	5652	2097	1024	596	388				
14000	5833	2121	1029	598	389				
15000	6000	2143	1034	600	390				
16000	6153	2162	1039	601	390				
17000	6296	2179	1043	603	391				
18000	6429	2195	1046	604	391				
19000	6552	2209	1050	605	392				
20000	6667	2222	1059	606	392				
30000	7500	2308	1071	612	395				
40000	8000	2353	1081	615	396				
50000	8333	2381	1087	617	397				
60000	8571	2400	1091	618	397				
70000	8750	2414	1094	619	398				
80000	8889	2424	1096	620	398				

The units of observation do not exceed 5% error in the accuracy of the overall survey complex

We analyzed the main etiological factors in the development and progression of AF, the prevalence of the main clinical forms of AF (paroxysmal, persistent, longstanding persistent and permanent) depending on the presence of COVID-19. Patients without valvular heart disease were assessed for risk of TEC using the CHA₂DS₂-VASc score recommended by the ESC [1,2,18].

Bleeding risk was assessed using the HAS-BLED score also recommended by the ESC [1,2,18,19].

The study of the situation regarding the compliance of anticoagulant use with the current ESC recommendations (2020) was conducted by analyzing the structure of pharmacological prevention of TEC at the time of the study.

Objective data obtained through instrumental and laboratory examinations at the screening stage include: measurement of blood pressure (BP) and heart rate, anthropometric parameters (height, body weight, waist and hip circumference), ECG recording in 12 leads at rest and daily Holter ECG monitoring in case of suspected AF.

ECG registration at rest was performed in a specially adapted and equipped room, using a computer system "CardioSys" (KAI-MEDICA, Ukraine). Immediately before the scheduled ECG registration, the patient should not eat, smoke, or drink stimulating drinks (tea, coffee, "energy drinks").

In persons with clinical and ECG signs of AF, Holter ECG was performed in conditions of free movement of the patient using the computer system "CardioSens+" (KAI-MEDICA, Ukraine) in the laboratory of Cardiac Arrhythmias of RSCSPMC. A 5-channel recorder was used, allowing to form 3 monitor leads corresponding to leads III, V1-2, and V5 of the standard ECG. During the study, patients filled out a diary in which they noted the nature of activity, their sensations, and the time of medication administration. The diary was used for a retrospective comparison of the patient's sensations and the character of heart rhythm disturbance at a certain moment of the day. The number and severity of heart rhythm disturbances were assessed during Holter ECG.

Table №2.

	The scheme of the formation of the study
	The (urban and rural) FP№3 of Gulistan city and FP№14 of Gulistan district of
Step 1	Syrdarya province with a total population of 29577 people (22165 (FP№3) and 7412
	(FP№14) population, respectively) were randomly selected.
Step 2	Using an electronic mathematical program, 1064 persons were randomly selected for
Step 2	FP№3 of Gulistan city and 812 persons for FP№14 of Gulistan district.
	Determination of the prevalence of cardiovascular diseases including CVDs including
Step 3	AF by screening 1064 persons from the selected FP№3 of Gulistan city and 812
_	persons from FP№14 of Gulistan district.
	Identified patients with AF underwent in-depth examination to review data on the
Step 4	prevalence of various forms of this arrhythmia and compliance of TEC prevention by
	anticoagulant use with current recommendations.

The scheme of the formation of the study

Statistical processing of the obtained results was carried out using the standard data analysis package "Microsoft Office Excel 2010", program "Statistica 10.0". The conformity of the data to the normal law of distribution was evaluated. We determined: sample arithmetic mean X; sample standard deviation (standard deviation) - SD. The results are presented as X±SD. Using the methods of parametric and nonparametric statistics, Student's t test, Mann-Whitney test, χ^2 test were

determined at different levels of significance (p). p<0.05 was taken as statistical reliability of differences.

Results of the study. According to the results of the study in FPN $_{23}$ of Gulistan city, it was found that (Table N $_{23}$) the mean age of the examined persons was 45.11 ± 16.63 years, while the mean age of women was higher: 45.57 ± 16.68 years vs. 44.69 ± 16.58 years, and the male/female ratio was 51.97% and 48.03%, respectively.

In 532 (50%) out of 1064 persons examined, medical documents did not contain information on diseases of cardiovascular and other systems, and therefore they were qualified as practically healthy persons. The proportion of practically healthy individuals was 55.1% among men and 44.4% among women ($\chi 2=5.949$; p=0.0147). The most frequently detected diseases were hypertension (HTN) and/or ischemic heart disease (IHD) - in 28.38% of the residents; indications for chronic rheumatic heart valve disease (RHVD) were detected in only 0.19% of the examined persons.

A history of post-infarction cardiosclerosis (PICS) was found in 1.13% and 0.85% of patients, respectively, and while PICS morbidity was slightly higher in women ($\chi 2=3.548$; p=0.0596), the rates of stroke were higher in men ($\chi 2=2.446$; P=0.1179). At the same time, women had a slightly higher group mean BMI than men: 26.95 ± 5.7 vs. 26.42 ± 4.14 (P=0.0813), while men were slightly more likely (1.5-fold) to have type 2 diabetes mellitus. It should be noted that 207 (19.5%) of the examined persons noted the fact of COVID-19 infection, with different degrees of exposure: discharge from hospital, MSCT/ chest X-ray, positive results of PCR/immunoglobulin G or M test, or from the words. As shown in Table №3, 20.1% of men and 18.8% of women reported having COVID-19 (Table №3).

Simplified analysis of medical documents, standard ECG, and Holter ECG as needed in a random sample of 1064 adults (over 18 years old) of polyclinic N_{23} in Gulistan city revealed the presence of cardiovascular diseases in 28.57% of the examined, another 21.43% had a record of diseases of other systems (gastrointestinal, respiratory, endocrine, oncological and other diseases). Every fifth person surveyed noted the fact of having suffered COVID-19. Consequently, 50% of residents qualified as practically healthy.

Table №3. Clinical characteristics of the examined persons in FP No 3 of Gulistan city									
Genera	l group			Men		Women			
(n=1	064)		(r	n=553 (51,97%))	(1	n=511 (48,03%))			
Age (years)	45,1	$1 \pm 16,63$		$44,69 \pm 16,58$		$45,57 \pm 16,68$			
Height (cm)	1,6	$4 \pm 0,08$		$1,68 \pm 0,08$	$1,60 \pm 0,07$				
Weight (kg)	$72,00 \pm 13,93$			$74,62 \pm 12,85$	$69,21 \pm 14,50$				
BMI	26,0	$58 \pm 4,96$	$26,42 \pm 4,14$		$26,95 \pm 5,7$				
			Di	iagnosis					
Healthy people	532	50,0%	305	57,33%/ 55,15%	227	42,67%/44,42%			
CHD/HTN	302	28,38%	149	49,34%/26,94%	153	50,66%/29,94%			
RHVD	2	0,19%	2	100,0%/ 0,36%	0	0/0			
Others	228	21,43%	97	42,54%/ 17,54%	131	57,46%/25,64%			

Associated diseases and/or complications										
Presence of	12	1,13%	3	25,0%/0,54%	9	75,0%/1,76%				
PICS (from										
CHD/HTN										
patients)										
History of	9	0,85%	7	77,78%/ 1,27%	2	22,22%/0,39%				
STEMI										
Type 2 DM	33	3,10%	20	60,61%/ 3,62%	13	39,39%/2,54%				
Covid-19	207	19,45%	111	53,62%/20,07%	96	46,38%/ 18,79%				

Similar analysis of the data from FPN $_{214}$ of Gulistan district, Syrdarya province showed that the average age of patients was 47.01 ± 15.06 years, while the average age of men was higher: 48.27 ± 15.19 vs. 46.97 ± 15.09 , and the male/female ratio was 51.97% and 48.03%, respectively (Table N $_{24}$).

In 272 (33.5%) out of 812 subjects, medical documents did not contain information on diseases of cardiovascular and other systems; therefore, they were qualified as practically healthy persons. The proportion of practically healthy individuals was 36.49% among men and 30.26% among women ($\chi 2=3.527$; p=0.0604).

Table №4. Clinical characteristics of examined persons in FP No 14 of Gulistan district									
Genera	al Group			Men	Women				
(n=	:812)			422 (51,97%)		390 (48,03%)			
Age (years)	47,01	$\pm 15,06$		$48,27 \pm 15,19$		$46,97 \pm 15,09$			
Height (cm)	1,66	$\pm 0,08$		$1,71 \pm 0,07$		$1,66 \pm 0,10$			
Weight (kg)	73,94	$\pm 15,15$		$77,75 \pm 15,39$		73,87 ± 15,28			
BMI	26,77	$7 \pm 5,07$		$26,69 \pm 4,8$		$26,74 \pm 5,12$			
]	Diagnosis					
Healthy people	272	33,50	154	56,62%/36,49%	118	43,38%/30,26%			
CHD/HTN	279	34,36	163	163 58,42%/38,63%		41,58%/29,74%			
RHVD	0	0,00	0	0/0	0	0/0			
ILC	0	0,00	0	0/0	0	0/0			
Others	261	32,14	105	40,23%/24,88%	156	59,77%/40,0%			
		Associate	d disea	ases and/or complication	ons				
Presence of PICS (from	12	4,30	8	66,67%/ 1,90%	4	33,33%/1,03%			
CHD/HTN patients)									
History of STEMI	3	0,37	1	33,33%/ 0,24%	2	66,67%/0,51%			
type 2 DM	26	3,20	14	53,85%/3,32%	12	46,15%/3,08%			
Covid-19	47	5,79	27	57,45%/6,40%	20	42,55%/ 5,13%			

Hypertension (HD) and/or IHD were the most frequently detected diseases in 34.36% of residents, while no indication for chronic RHVD disease was found. A history of post-infarction cardiosclerosis (PICS) was detected in 4.30% and cerebral circulatory disorders in 0.37% of patients, respectively; while PICS morbidity was slightly higher among men ($\chi 2=1.049$; p=0.3057), the rates of STEMI were higher among women ($\chi 2=0.401$; p=0.5267). At the same time, women had a slightly higher group-average BMI than men: 26.74 versus 26.69 (p=1.0000), while men were slightly more likely (1.17-fold) to have type 2 diabetes mellitus. It should be noted

that 47 (5.79%) of the examined persons noted the fact of COVID-19 infection, with different degrees of exposure: discharge from hospital, MSCT/ chest X-ray, positive results of PCR/ immunoglobulin G or M test, or by words. As shown in Table N_{24} , 6.40% of males and 5.13% of females reported having COVID-19.

Thus, simplified analysis of medical documents, standard ECG, as well as Holter ECG as needed in a random sample of 812 adults (over 18 years old) of polyclinic №14 of Gulistan district. Gulistan revealed the presence of cardiovascular diseases in 34.36% of the examined, another 32.14% had a record of diseases of other systems (gastrointestinal, respiratory, endocrine, oncological, and other diseases). Every fifth person surveyed noted the fact of having undergone COVID-19— consequently, 33.50% of residents qualified as practically healthy.

Table No. Clinical characteristics of patients with AF												
				stan city.	1		FP №14 of Gulistan district					
	T	otal		Men	W	omen	T	'otal	Men		Women	
AF	、 、	1,03%)		53,60%)	4 (3	6,40%)	4 (0	,49%)	2 (5	50,0%)	2 (50,0%)
Age (years)	6	4,91	6.	3,71 ±	67	7,0 ±	50	8 ±2,6	60	5 ± 0.7	57	0 ± 2.8
Age (years)	±]	14,30		1,86		9,78	58,	8 ±2,0	00,	$5 \pm 0, 7$	57,	$,0 \pm 2,0$
Height (cm)	1,68	$3\pm 0,10$	1,7	$1 \pm 0,10$	1,61	$\pm 0,06$	1,6	$0 \pm 0,0$	1,7	$7 \pm 0,0$	1,	$6 \pm 0,0$
Weight (kg)	9	7,36		$9,43 \pm$	76	,25 ±	80	5,3 ±	80.0	$) \pm 28,3$	02	$5 \pm 10,6$
weight (kg)	±2	26,99		25,83		2,61	1	8,9		,	<i>J</i> 2,	$5 \pm 10,0$
BMI	34 4	$\pm 7,62$		7,32 ±		,28 ±	327	$7 \pm 7,8$		$8,9 \pm$	36	6 ± 3.5
DMI	,-,-	- 1,02		7,84		3,98	52,	/ ± /,0	1	0,04	50,	$,0 \pm 5,5$
	1					gnosis				I		
CHD/HTN	10	90,9	7	70	3	30	4	100	2	50	2	50
RHVD	0	0,0	0	0	0	0	0	0,0	0	0	0	0
PICS	4	40,0	2	50	2	50	0	0,0	0	0	0	0
Obesity	7	63,6	6	85,7	1	14,3	3	75,0	1	33,3	2	66,7
type 2 DM	2	18,2	2	100	0	0	1	20,0	1	100	0	0
STEMI	2	18,2	1	50	1	50	0	0,0	0	0	0	0
					CH	F stage						
CHF 0.	3	27,27	2	66,67	1	33,33	0	0	0	0	0	0
CHF 1	2	18,18	2	100,0	0	0,00	2	50,0	1	50,0	1	50,0
CHF 2A	5	45,45	2	40,0	3	60,00	2	50,0	1	50,0	1	50,0
CHF 2B	1	9,091	1	100,0	0	0,00	0	0	0	0	0	0
				NY	HA c	lass of (CHF					
FC 1	0	0	0	0	0	0	0	0	0	0	0	0
FC 2	2	18,18	2	100	0	0	2	50,0	1	50,0	1	50,0
FC 3	6	54,55	3	50	3	50	2	50,0	1	50,0	1	50,0
FC 4	0	0	0	0	0	0	0	0	0	0	0	0
AF types												
Paroxysmal	0	0	0	0	0	0	0	0	0	0	0	0
Persistent	3	27,27	2	66,67	1	33,33	1	25,0	0	0	1	100
Long-												
standing	0	0	0	0	0	0,00	1	25,0	1	25,0	0	0
Persistant												
Permanent	8	72,73	5	62,5	3	37,50	2	50,0	2	100,0	0	0
The		- 1- : 4		- f		1		1		41		

Table №5. Clinical characteristics of patients with AF

The main objective of our study was to determine the compliance of pharmacological prevention of thromboembolic complications to the requirements of

the current ESC recommendations 2020 and the standards of diagnostics and treatment of AF of the Ministry of Health of the Republic of Uzbekistan 2022.

Table №6. Age characterization of AF occurrence with regard to gender:
(a) FP №3 of Gulistan city, Syrdarya province;

Age Number		AF in the	general	AF in		AF in men		
(18-91)	of people	U	group					
	surveyed	Absolute	%	Absolute	%	Absolute	%	
18-19	42	0	0	0	0	0	0	
20-29	190	0	0	0	0	0	0	
30-39	216	0	0	0	0	0	0	
40-49	180	2	1,11	1	0,56/50,0	1	0,56/50,0	
50-59	177	1	0,56	0	0	1	0,56/100	
60-69	176	4	2,27	1	0,57/25	3	1,70/75	
70-79	67	2	2,99	1	1,49/50,0	1	1,49/50,0	
80-89	14	1	7,14	0	0	1	7,14/100,0	
90-91	2	1	50,0	1	50,0/100,0	0	0	
Total	1064	11	1,03	4	0.7%	7	1.27%	
b - FP №1	4 of Gulista	n district of	f Syrdarya	a province;				
1 ~~~	Number	AF in the	general	AF in	women	AF in men		
	of people	gro	up					
(18-94)	surveyed	Absolute	%	Absolute	%	Absolute	%	
18-19	12	0	0	0	0	0	0	
20-29	94	0	0	0	0	0	0	
30-39	186	0	0	0	0	0	0	
40-49	175	0	0	0	0	0	0	
50-59	153	2	1,31	2	1,31	0	0	
60-69	136	2	1,47	0	0	2	1,47	
70-79	43	0	0	0	0	0	0	
80-89	10	0	0	0	0	0	0	
90-94	3	0	0	0	0	0	0	
Total	812	4	0,49	2	0,25	2	0,25	

As can be seen from Table Neq6 (a), in FP Neq3 of Gulistan city, Syrdarya region, in the age group up to 40 years old, AF was practically not detected. In the age group, 40-49 years AF was detected in 1.11%, in the group 50-59 years AF was detected in 0.56%, in the age category 60-69 years - in 2.27% of the surveyed. It should be noted that the detection rate of AF increased with age, reaching a maximum in the category of 90-91 years (50%). In the age category over 80 years, the prevalence of AF was 12.5%. When analyzing rural areas, as indicated in Table 5 (b), AF was practically not detected in the age group up to 50 years and above 70 years. In the age group of 50-59 years, AF was found in 1.31% and in the age group of 60-69 years, AF was found in 1.47%.

In general, the trend of increasing prevalence of AF with age in our sample is consistent with the well-known fact [1,2,3]. However, the prevalence percentages in our sample were lower than in European and North American countries.

The main etiologic factor of AF in both urban (FP №3) and rural (FP №14) areas was HTN and/or CHD - in 90.9% and 100%, respectively. Surprisingly for us, the rheumatic etiology of AF was not revealed in either FP№3 or FP№14. As is

known, a high proportion of valvular etiology is characteristic of developing countries, where primary and secondary prevention of rheumatic heart disease is not at an adequate level. In this regard, in developing countries, and in particular in Uzbekistan, the ratio of patients requiring prevention of TEC with warfarin is significantly higher.

When analyzing the data of FPNeq 4 in urban areas, a higher (more than 1.5 times) prevalence of AF among men was revealed both in absolute (7 vs. 4) and relative values (63.6% vs. 36.4%). The high prevalence of AF among men in our sample coincides with the data of Revishvili A.Sh. indicated in thematic monographs. At the same time, the detection rate of AF in many studies is higher among women [20]. At the same time, in rural areas (FP Ne14), no gender difference between the detection of AF among men and women was found (2 vs. 2). The explanation for this may be the detection of a small number of patients with AF.

The question of the adequacy of TEC prevention is of certain interest. As it follows from Table 7, the risk of TEC assessed by CHA_2DS_2 –VASc score, and varied from 2 to 6 points, and on average in the group for FPNo3 was 3,64±1,80 points and slightly lower 2,8±1,0 points for FPNo14, while the risk of bleeding according to HAS-BLED score on the background of antithrombotic therapy was 1,73±1,1 points and 1,0±0,0 points for the compared outpatient clinics, respectively. These data indicate that absolutely all patients with AF had indications for anticoagulant therapy (ACT).

		3 of Gulistan /rdarya regio	• /	FP №14 of Gulistan district of Syrdarya region				
	General group	Men	Women	General group	Men	Women		
CHA2DS2- VASc	2,8±1,0	2,5±0,7	3,0±1,4	3,64±1,80	3,14±1,35	4,5±2,38		
HAS-BLED	1,0±0,0	1,0±0,0	1,0±0,0	1,73±1,1	1,57±0,98	2,0±1,41		

Table №7. Assessment of the CHA2DS2-VASc and HAS-BLED depending on gender

The analysis of the characterization of pharmacological prevention of TTE showed that at the moment of treatment even though almost all patients with AF had a high risk of TTE according to scale CHA_2DS_2 -VASc>2 points, only every fourth patient in both urban (27%) and rural (25%) polyclinics of Syrdarya region received ACT (Table N \ge 8).

At the same time, 9.1% in FP№3 and 25% of patients in FP№14 who were on ACT reception took DOACs (rivaroxaban). VKAs, in particular warfarin, were taken by 18.2% of patients in FP№3 of Gulistan city, while in rural areas the prescription of this drug was not revealed. Both in urban (54,5%) and rural (50%) polyclinics more than 50% of patients took antiplatelet therapy (acetylsalicylic acid or clopidogrel) not included in the ESC recommendations as a prevention of TEC in AF. In addition, 25% of patients in rural areas were not taking any antithrombotic therapy.

Table №8. Characteristics of pharmacological prevention of TEE at the prehospital stage depending on the etiologic factor.

European Journal of Research volume 0 issue 2 2024 mages 17 20	
European Journal of Research volume 9 issue 2 2024 pages 17-30	

	FP №3 of	Gulistan city, region	, Syrdarya	FP №14 of Gulistan district of Syrdarya region				
	General group n=11 (100%)	The valvular etiology of AF n=0	Non- valvular etiology of PD n=11 (100%)	General group n = 4 (100%)	Valvular etiology of AF n = 0	Non- valvular etiology of AF. n= 4 (100%)		
VKAs	2 (18,2%)	0	2 (18,2%)	0	0	0		
DOACs	1 (9,1%)	0	1 (9,1%)	1 (25,0%)	0	1 (25,0%)		
Antiplatelet drugs	6 (54,5%)	0	6 (54,5%)	2 (50,0%)	0	2 (50,0%)		
DOACs + Antiplatelet drugs	0	0	0	0	0	0		
Without AT therapy.	2 (18,2%)	0	2 (18,2%)	1 (25,0%)	0	1 (25,0%)		

Discussion of the findings. As is known, the leading causes of cardiovascular mortality are myocardial infarctions and cerebral strokes. The estimated number of strokes in Uzbekistan is not less than 76 thousand/year [14,15]. Strokes are characterized by high mortality (up to 30%) and disability. Up to 30% of all strokes develop in patients with AF, detected in 1-2% of the population. Consequently, the estimated number of patients with AF in Uzbekistan is not less than 330-340 thousand annually, and 25 thousand of them develop strokes, including more than 8 thousand fatal. Strokes on the background of AF are characterized by higher mortality and disability rates, compared to strokes, frolicking in patients who do not have this arrhythmia. Therefore, the requirements for the prevention of TEC and, first of all, ACT in this category of patients have become much stricter. Thus, oral anticoagulants (DOAC) are recognized as the drugs of choice, and when prescribing vitamin K antagonists (VKAs), and in particular, warfarin, the recommended level of Time in therapeutical range (TTR) is increased from 60 to 70% [1].

Previously, we found extremely low adherence of physicians and patients in stroke prevention (less than 7%), and, in particular, prescription of anticoagulants and antiarrhythmic drugs [21]. In this regard, there is an urgent need to develop and implement optimal methods of pharmacological prevention of TEC (warfarin or new oral anticoagulants) and recurrence in patients with AF, taking into account the peculiarities of the healthcare organization in Uzbekistan and the requirements for personalized medicine. At the same time from the pharmacoeconomic point of view warfarin is a more acceptable means of preventing TEC (economic benefit of at least 300,000 sums/month per 1 patient in comparison with taking DOACs, for example, rivaroxaban). However, in most district centers of the country, there is no possibility of regular (at least once/month) and adequate monitoring of warfarin efficacy by Thus. most patients who need long-term (lifelong) prevention INR. of thromboembolic complications (ischemic strokes, pulmonary embolism) in the real situation do not receive it either due to the high cost of new anticoagulants (in Uzbekistan-Rivaroxaban, Apixaban), or due to the lack of possibility of effective control of warfarin intake. In connection with the above-mentioned, the determination of the real situation on the frequency of various forms of AF among the population and the adequacy of prevention of ischemic strokes in this category of patients is the solution to an extremely important socio-economic problem.

Information on the frequency of clinical forms of AF in the territory of individual family polyclinics in the Syrdarya region, as well as compliance of prevention of TEC by different variants of pharmacotherapy with the current recommendations of the European Society of Cardiology (2020) and standards of the Ministry of Health of Uzbekistan (2022), will allow obtaining data on the real need for prevention of TEC in this category of patients, with the possibility of subsequent extrapolation of these data on the regional score in other regions of Uzbekistan.

The relevance of this problem is evidenced by the inclusion in the order of the President of the Republic of Uzbekistan. №-103 of 26.01.2022 "On measures to prevent and improve the quality of treatment of cardiovascular diseases" paragraph on the need to equip the FP of each district of our country with a coagulometer, which allows to ensure regular monitoring of the effectiveness and safety of ACT with warfarin (blood test for INR), especially in socially disadvantaged populations.

Conclusions:

1. The prevalence of AF among the adult population of some polyclinics of Gulistan city. Gulistan (1.03%) and 2 times higher than among the population of rural polyclinics of Syrdarya region (0.49%).

2. The main etiologic factor of AF in all polyclinics was HTN and/or CHD. Low alertness of physicians about CPHD was revealed. At the same time, more than half of them were diagnosed with a permanent form of AF. It was found that, in general, patients with AF of different clinical forms in both rural and urban areas have a high risk of TEC/ischemic stroke, with a low risk of bleeding according to the CHA_2DS_2 -VASc and HAS-BLED scales, respectively.

3. Unfortunately, at the outpatient stage corresponding to ESC recommendations (2020) and standards of Ministry of Health of the Republic of Uzbekistan 2022 on prevention of TEC in patients with AF, insufficient adequacy was revealed both in a separate urban (27%) and in rural (25%) polyclinics of Syrdarya region. Thus, more than 70% of AF patients are at high risk of death and disability.

Ethics Committee Approval: The study protocol was approved by the Local Ethics Committee of the Republican Specialized Scientific And Practical Medical Center Of Cardiology (approval number: 7, date: 11.01.2024).

Informed Consent: Informed consent was obtained from the selected patients before administering the study questionnaire. The protocol of informed consent for participation in the study complies with the requirements of the Helsinki Declaration on Bioethics and Human Rights;

Conflict of Interest: We do not declare any conflict of interest.

Financial Disclosure: This study received no financial support.

Reference.

1. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal (2016) 37, 2893–2962. doi:10.1093/eurheartj/ehw210

2. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal (2020) 00, 1-126. doi:10.1093/eurheartj/ehaa612

3. Mareev Yu.V., Polyakov D.S., Vinogradova N.G., Fomin I.V., Mareev V.Yu., Belenkov Yu.N., Ageev F.T., Artemjeva E.G., Badin Yu.V., Bakulina E.V., Galyavich A.S., Ionova T.S., Kamalov G.M., Kechedzhieva S.G., Koziolova N.A., Malenkova V.Yu., Malchikova S.V., Smirnova E.A., Tarlovskaya E.I., Shcherbinina E.V., Yakushin S.S. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF study. Kardiologiia. 2022;62(4):12-19. (In Russ.) https://doi.org/10.18087/cardio.2022.4.n1997

4. Марданов Б.У., Корнеева М.Н., Ахмедова Э.Б. Анализ последних международных клинических исследований по фибрилляции предсердий: тенденции и перспективы // Международный журнал сердца и сосудистых заболеваний. — 2015. — Т.3 — N_{28} — С. 11–17. [Mardanov BU, Korneeva MN, Ahmedova EB. Analysis of latest international guidelines for atrial fibrillation: trends and perspectives. Mezhdunarodnyi zhurnal serdca i sosudistyh zabolevanii. 2015;3(8):11–17. [In Russ).]

5. Gilyarov M.Yu., Konstantinova E.V. Atrial fibrillation as a risk factor for ischemic stroke. Consilium Medicum. 2015; 17 (9): 16–19.

6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:982-8. doi:10.1161/01.STR.22.8.983

7. Е. И. Баранова. Новые стандарты безопасности антикоагулянтной терапии при фибрилляции предсердий Российский кардиологический журнал. 2018;23(10):136–144. http://dx.doi.org/10.15829/1560-4071-2018-10-136-144

8. Кропачева Е.С., Землянская О.А., Добровольский А.Б., Панченко Е.П. варфарином: Эффективность длительной терапии влияние на частоту ишемических нарушений мозгового кровообращения И клинические предикторы их развития (результаты проспективного 10-летнего наблюдения) // Атеротромбоз. — 2017. — №2 — С. 115–130. [Kropacheva ES, Zemljanskaja OA, Dobrovol'skii AB, Panchenko EP. The efficacy of long-term warfarin therapy: the impact on the incidence of ischemic cerebrovascular disorders and clinical predictors of developing such disorders. (Results of a prospective 10-year follow-up study). Atherothrombosis J. 2017;(2):115-130. (In Russ).] doi: 10.21518/2307-1109-2017-2-115-130.

9. The Lancet Neurology. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease

Study 2019. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00252-0/fulltext?dgcid=raven_jbs_etoc_email#

10. World Stroke Organization. Fact Sheet. https://www.worldstroke.org/assets/downloads/WSO_Global_Stroke_Fact_Sheet.pdf

11. Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). AHJ. 2012;163(1):13–19. doi: 10.1016/j.ahj.2011.09.011.

12. Skirdenko YuP, Nikolaev NA, Livzan MA, Ershov AV. Anticoagulant Therapy for Atrial Fibrillation in Real Practice: Problems and Prospects. Annals of the Russian Academy of Medical Sciences. 2019;74(2):98–107. doi: 10.15690/vramn1116)

13. Диагностика и лечение фибрилляции предсердий. Клинические рекомендации [интернет]. / Под ред. акад. А.Ш. Ревишвили. — Всероссийское общество специалистов по клинической электрофизиологии, научное электрокардиостимуляции (ВНОА) в сотрудничестве с аритмологии и Российским кардиологическим обществом (РКО) и Ассоциацией сердечнососудистых хирургов России (ACCX); 2018. [Diagnostika i lechenie fibrillyatsii Klinicheskie rekomendatsii [Internet]. Ed by predserdii. Revishvili ASh. Vserossiiskoe Nauchnoe Obshhestvo specialistov po klinicheskoi jelektrofiziologii, Aritmologii I jelektrokardiostimuljacii (VNOA) v sotrudnichestve s Rossiiskim Kardiologicheskim obshhestvom (RKO) i Associacii serdechnososudistyh hirurgov Rossii (ASSH); 2018. (In Russ).] Доступно по: http://scardio.ru/rekomendacii/rekomendacii_rko_close/.

14. Каримов Ш.И., Юлбарисов А.А., Суннатов Р.Д. Диагностика и лечение больных с хронической сосудисто-мозговой недостаточностью ишемического генеза. Методическое пособие. Ташкент 2018г.

15. Каримов Ш.И., Юлбарисов А.А., Суннатов Р.Д. Диагностика и лечение больных с хронической сосудисто-мозговой недостаточностью ишемического генеза при сочетанном поражении коронарного русла. Методическое пособие. Ташкент 2018г.

16. Абсолютная точность и другие иллюзии. Секреты статистики. Пере Грима. ISBN: 978-5-9774-0682-6, 978-5-9774-0706-9 (т. 13) Год издания: 2014. https://www. livelib.ru/ book/1000943720-absolyutnaya-tochnost-i-drugie-illyuzii-sekrety-statistiki-pere-grima

17. Мангейм Дж.Б., Рич Р.К. Политология: Методы исследования. – М., 1997. С.517.

18. Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010 Jun;123(6):484-8. Review. PubMed ID: 20569748

19. Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med. 2011 Feb;124(2):111-4. PubMed ID: 20887966

20. Ревишвили А.Ш., Сулимов В.А. Фибрилляция и трепетание предсердий (практическое руководство) // Кардиология: Новости. Мнения. Обучение. 2022. №4 (31).

21. Курбанов Р.Д., Закиров Н.У., Ирисов Дж.Б., Ганиев Т.З., Режаббоев Х.А. Адекватность антитромботической терапии у больных с фибрилляцией предсердий в реальной клинической практике. Бюллетень Ассоциации Врачей Узбекистана. №1, 2017г. Стр 10-14.